Pfizer Q2 revenues $12.7B (-54% YoY); narrows FY revenue guidance to $67-70B

PFIZER INC

2023-Q2 EPS reported $1.38 revenue$31,015,000,000

Q2 reported diluted EPS $0.41 (-77% YoY); adjusted diluted EPS $0.67 (-67% YoY).
Comirnaty and Paxlovid combined revenue $1.6B; ex-COVID revenue grew 5% operationally.
Narrowed FY2023 revenue guidance to $67-70B (previously $67-71B); maintained adjusted EPS guidance $3.25-3.45.
Non-COVID operational growth expectation reduced to 6-8% from 7-9% due to label, ACIP recommendation, tornado damage.
Closed $31B debt offering to partly fund Seagen acquisition; transaction expected late 2023/early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported the second quarter of 2023 results: revenue $12,734, net income $2,327, EPS $0.41. Guidance reaffirmed.

Period: the second quarter of 2023
Revenue: $12,734
Net income: $2,327
EPS: $0.41
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of 2023 and 2022 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Second-Quarter Six Months 2023 2022 Change 2023 2022 Change Revenues $ 12,734 $ 27,742 (54%) $ 31,015 $ 53,402 (42%) Reported Net Income (2) 2,327 9,906 (77%) 7,870 17,769 (56%) Reported Diluted EPS (2) 0.41 1.73 (77%) 1.38 3.10 (56%) Adjusted (3) Income

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-23-000085

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.